Next Article in Journal
Acute Lupus Pneumonitis—Case Report and Literature Review
Previous Article in Journal
Lipoid Pneumonia—A Case of Refractory Pneumonia in a Child Treated with Ketogenic Diet
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 81
Issue 5
10.5603/ARM.35521
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Interstitial Pneumonia Connected with Rituximab Therapy—Case Report

by
Dorota Wyrostkiewicz
1,*,
Wojciech Skorupa
1,
Inga Barańska
2 and
Jan Kuś
1
1
I Klinika Chorób Płuc Instytutu Gruźlicy i Chorób Płuc w Warszawie, ul. Płocka 26, 01-138 Warszawa, Poland
2
Zakład Radiologii Instytutu Gruźlicy i Chorób Płuc w Warszawie, ul. Płocka 26, 01-138 Warszawa, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2013, 81(5), 453-459; https://doi.org/10.5603/ARM.35521
Submission received: 11 January 2013 / Revised: 22 August 2013 / Accepted: 22 August 2013 / Published: 22 August 2013

Abstract

Rituximab (RTX) is a monoclonal antibody against the CD20 antigen found on the surface of B cells. RTX causes cell lysis and is therefore used to treat lymphomas, leukaemias, transplant rejection and certain autoimmune disorders. Pulmonary adverse events associated with RTX have been reported in literature. We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincri- stine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Symptoms and radiological changes resolved with prednisone therapy.
Keywords: interstitial pneumonia; adverse effects; monoclonal antibodies; rituximab interstitial pneumonia; adverse effects; monoclonal antibodies; rituximab

Share and Cite

MDPI and ACS Style

Wyrostkiewicz, D.; Skorupa, W.; Barańska, I.; Kuś, J. Interstitial Pneumonia Connected with Rituximab Therapy—Case Report. Adv. Respir. Med. 2013, 81, 453-459. https://doi.org/10.5603/ARM.35521

AMA Style

Wyrostkiewicz D, Skorupa W, Barańska I, Kuś J. Interstitial Pneumonia Connected with Rituximab Therapy—Case Report. Advances in Respiratory Medicine. 2013; 81(5):453-459. https://doi.org/10.5603/ARM.35521

Chicago/Turabian Style

Wyrostkiewicz, Dorota, Wojciech Skorupa, Inga Barańska, and Jan Kuś. 2013. "Interstitial Pneumonia Connected with Rituximab Therapy—Case Report" Advances in Respiratory Medicine 81, no. 5: 453-459. https://doi.org/10.5603/ARM.35521

Article Metrics

Back to TopTop